The global ventricular fibrillation treatment market is slated to reach a valuation of US$ 9.19 billion in 2023. According to Future Market Insights, the market is expected to grow at an 8.5% CAGR until 2033, valued at US$ 20.78 billion.
The increase in the number of cardiac cases worldwide is the major factor that is driving the growth of the global ventricular fibrillation treatment market. The increasing focus on healthcare across different regions is another factor that is expected to drive the growth of the market. Additionally, the growth in medical tourism in certain developing countries will also lead to a contribution to the global ventricular fibrillation treatment market.
But it is also considered that the high cost of the technologies required in the treatment of the global ventricular fibrillation market is coupled with strict regulations that will hamper the growth of the industry.
Also, there has been a noticeable rise in the number of patients suffering from Ventricular fibrillation is disorderly and irregular electrical activity in the heart’s ventricles. The ventricles, in turn, do not contract and pump blood out of the heart into the body where VFib is an emergency. So, if VFib develops, the body will not receive the blood it needs as the heart is no longer pumping.
The only way to correct a heart that is experiencing VFib is to give it an electrical shock with a defibrillator. If the shock is administered in time, a defibrillator can revert the heart to a normal, healthy rhythm.
| Attributes | Details |
|---|---|
| Projected Forecast Value (2023) | US$ 9.19 billion |
| Projected Forecast Value (2033) | US$ 20.78 billion |
| Growth rate | 8.5% CAGR |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global Ventricular Fibrillation Treatment Market grew at a CAGR of 6.8% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.
Earlier, the most common presentation for VF is sudden collapse from cardiac arrest leading to SCD. This results from improper ventricular contraction resulting in low cardiac output. Patients may demonstrate signs of acute MI such as chest pain, shortness of breath, nausea, and vomiting before the event. Patients with a known history of coronary artery disease or congestive heart failure may show a worsening of chronic symptoms such as angina, dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and pedal edema. At the time of presentation, patients are unconscious, unresponsive, and have no palpable pulse. Without prompt action, this leads to death within the next few minutes. Patients with ICD for primary or secondary prevention can experience shock from ICD firing at the time of experiencing VF.
Nowadays, ICDs can reduce the risk of sudden cardiac death by the development of an entirely subcutaneous ICD (S-ICD) system with efficacy similar to that of conventional ICD in terminating VF which has been a major advance in device technology. Although randomized comparative data are not yet available, pooled data from the EFFORTLESS and IDE trials have shown the S-ICD to be a safe and effective alternative to conventional transvenous ICDs- especially in younger patients with HCM, genetic channelopathies, and adult complex congenital heart disease.
Introduction of interventional cardiology devices
The high utilization of cardiac diagnostics and monitoring devices for ventricular fibrillation treatment is boosting the sales of diagnostic devices. Some of the devices are Holter monitors, ECGs, diagnostic catheters, etc. The advent of portable and digital systems and the expanding usage of these devices in interventional medical procedures like catheter placement are thus fuelling the demand for devices required in the treatment of the ventricular fibrillation industry.
A surge in the worldwide prevalence of cardiovascular disorders
Global demand for electrophysiology devices is raising as ventricular fibrillation and other heart disorders become more common. The Centers for Disease Control and Prevention (CDC) estimate that 0.5% of the world’s population is having ventricular fibrillation where the disorder affects 2% of people under age 65, whereas it has affected about 9% of people over the age of 65 globally.
Principal Consultant
Focus on investing in R&D products
There has been a noticeable rise in the number of patients suffering from VF where the risk is noticed in patients suffering from hypertension, obesity, and other cardiovascular diseases. But this increase in the pool of patients will also significantly bring ample opportunities.
Companies are not only focusing to invest in R&D for enhancing their product, services, technology, and processes but also in creating new products where companies are also focusing on adding new features for the existence of new products for enhancing their product portfolio.
High efficiency of ablation procedures will offer several business growths
The electrophysiology market from the EP ablation catheters segment held around 48% revenue share in 2022. Among EP ablation catheters, cryoablation is majorly a growing segment that is owing to its superior therapeutic advantages. Ablation catheters deliver minimal invasive ways to efficiently treat a wide range of arrhythmias with lesser pain and blood loss.
Adoption of ventricular restoration systems
North America is expected to hold the largest market share in the ventricular fibrillation market. This is attributed to the high demand and adoption of ventricular restoration systems. This well-established healthcare system along with skilled professionals will also serve as one of the major factors leading to the dominance of this region in the global ventricular fibrillation treatment market.
Rapid advancement in the medical sector
The market in Asia-Pacific is assumed to grow at a rapid rate throughout the anticipated time. The region’s expansion is driven by a high proportion of elderly people with rising heart risk. Also, it is expected that the developing healthcare infrastructure, greater patient awareness, and higher healthcare spent in the nations such as China, India, and Japan.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Catheter ablation will have a dominant share
Catheter ablation by PDN in patients with recurrent VF or polymorphic VT in the absence of regional substrate or distinct triggers was effective in terms of reducing arrhythmia recurrence and ICD shock burden.
Catheter ablation by PDN was technically feasible with acceptable procedure durations and low complication rates.
Electrocardiograms have a dominant share
This quick and painless test measures the electrical activity of the heart. Sticky patches (electrodes) are placed on the chest and sometimes the arms and legs. Wires connect the electrodes to a computer, which displays the test results. An ECG can show if the heart is beating too fast or too slowly. In a person suffering from ventricular fibrillation, the ECG usually shows a heartbeat of about 300 to 400 beats a minute.
Atricure provides a range of products including cardiac ablation devices, left atrial appendage occlusion devices, and intraoperative testing equipment. The company went public in 2005. In Oct 2015, it acquired nContact, a privately held developer of cardiac ablation solutions.
Provider and developer of an AI-based cardiac ablation therapy software and device. It offers the product CathVision Cube which can visualize electrophysiology signals to support delivering accurate therapy. CathVision Cube is a product that comprises low-noise ablation therapy with signal quality to stream, analyze and store EP signals. The interface provides a real-time streaming review window for analysis using AI algorithms for clinical decision support. The software integrated into the device helps in analyzing and storage of EP signals.
Some of the prominent players in the global market for VF treatment are
Some of the important developments of the key players in the market are
In March 2021, the Rankin government announced that all public schools in Nova Scotia would be provided with automated external defibrillators. The government invested US$ 700,000.
In February 2022, Medtronic said that Freezor and Freezor Xtra Cardiac Cryoablation Focal Catheters, the first and only ablation catheters licensed to treat the rising prevalence of juvenile Atrioventricular Nodal Reentrant Tachycardia, had obtained FDA extended approval (AVNRT).
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 8.5% from 2023 to 2033 |
| Market value in 2023 | US$ 9.19 Billion |
| Market value in 2033 | US$ 20.78 Billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD Billion for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customisation Scope | Available on Request |
The market is valued at US$ 9.19 billion in 2023.
Abbott, Medtronic, and Boston Scientific Corporation are key market players.
The primary consumer for the ventricular fibrillation treatment market is the healthcare industry.
The market is estimated to reach US$ 20.78 billion by 2033.
The market is forecast to register a CAGR of 8.5% throughout 2033.
1. Executive Summary | Ventricular Fibrillation Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnostic techniques 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Diagnostic techniques, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnostic techniques, 2023 to 2033 5.3.1. Electrocardiogram 5.3.2. Blood Test 5.3.3. Echocardiogram 5.3.4. Electrophysiology Study 5.3.5. X-ray 5.4. Y-o-Y Growth Trend Analysis By Diagnostic techniques, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Diagnostic techniques, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 6.3.1. CPR 6.3.2. Defibrillation 6.3.3. Medication 6.3.4. Catheter ablation 6.3.5. Left cardiac sympathetic denervation 6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. South Asia 7.3.5. East Asia 7.3.6. Oceania 7.3.7. MEA 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Diagnostic techniques 8.2.3. By Treatment 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Diagnostic techniques 8.3.3. By Treatment 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Diagnostic techniques 9.2.3. By Treatment 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Diagnostic techniques 9.3.3. By Treatment 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Diagnostic techniques 10.2.3. By Treatment 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Diagnostic techniques 10.3.3. By Treatment 10.4. Key Takeaways 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. India 11.2.1.2. Malaysia 11.2.1.3. Singapore 11.2.1.4. Thailand 11.2.1.5. Rest of South Asia 11.2.2. By Diagnostic techniques 11.2.3. By Treatment 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Diagnostic techniques 11.3.3. By Treatment 11.4. Key Takeaways 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Diagnostic techniques 12.2.3. By Treatment 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Diagnostic techniques 12.3.3. By Treatment 12.4. Key Takeaways 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Australia 13.2.1.2. New Zealand 13.2.2. By Diagnostic techniques 13.2.3. By Treatment 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Diagnostic techniques 13.3.3. By Treatment 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Diagnostic techniques 14.2.3. By Treatment 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Diagnostic techniques 14.3.3. By Treatment 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Diagnostic techniques 15.1.2.2. By Treatment 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Diagnostic techniques 15.2.2.2. By Treatment 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Diagnostic techniques 15.3.2.2. By Treatment 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Diagnostic techniques 15.4.2.2. By Treatment 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Diagnostic techniques 15.5.2.2. By Treatment 15.6. United kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Diagnostic techniques 15.6.2.2. By Treatment 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Diagnostic techniques 15.7.2.2. By Treatment 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Diagnostic techniques 15.8.2.2. By Treatment 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Diagnostic techniques 15.9.2.2. By Treatment 15.10. India 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Diagnostic techniques 15.10.2.2. By Treatment 15.11. Malaysia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Diagnostic techniques 15.11.2.2. By Treatment 15.12. Singapore 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Diagnostic techniques 15.12.2.2. By Treatment 15.13. Thailand 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Diagnostic techniques 15.13.2.2. By Treatment 15.14. China 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Diagnostic techniques 15.14.2.2. By Treatment 15.15. Japan 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Diagnostic techniques 15.15.2.2. By Treatment 15.16. South Korea 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Diagnostic techniques 15.16.2.2. By Treatment 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Diagnostic techniques 15.17.2.2. By Treatment 15.18. New Zealand 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Diagnostic techniques 15.18.2.2. By Treatment 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Diagnostic techniques 15.19.2.2. By Treatment 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Diagnostic techniques 15.20.2.2. By Treatment 15.21. Israel 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Diagnostic techniques 15.21.2.2. By Treatment 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Diagnostic techniques 16.3.3. By Treatment 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. CardioDx, Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Advanced Instrumentations Inc. 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Cameron Health, Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Bexen Cardio 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. CU Medical Systems, Inc. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Biotronik SE & Co. KG 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Pfizer Inc. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Heritage Pharmaceuticals Inc. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Baxter International Inc. 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Lawson Health Research Institute 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Ventricular Fibrillation Treatment Market
